Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activities of doripenem (S-4661) against drug-resistant clinical pathogens.

Antimicrobial agents and chemotherapy - 1 Aug 2004

Jones Ronald N, Huynh Holly K, Biedenbach Douglas J

Abstract excerpt

Doripenem (formerly S-4661), a new 1-beta-methyl carbapenem, was challenged with a worldwide collection of 394 drug-refractory isolates. For endemic extended-spectrum beta-lactamase- and stably derepressed AmpC-producing enteric bacilli, the doripenem MICs at which 90% of the isolates were inhibited (MIC90s) were 0.03 to 0.5 microg/ml, generally lower than those of comparator carbapenems. A greater proportion of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacteria
Share to Bacterial Infections
Share to Carbapenems

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Bacterial

Share to Genotype

Share to Gram-Negative Bacteria

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 15273134
DOI: 10.1128/AAC.48.8.3136-3140.2004
PMCID: PMC478547

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Activities of doripenem (S-4661) against drug-resistant clinical pathogens.PMID 15273134Read ↗

In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains.Semantic proximity Read ↗

Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases.Semantic proximity Read ↗

Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carbapenem doripenem.Semantic proximity Read ↗

Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.Semantic proximity Read ↗

Pharmacodynamic activity of ertapenem versus multidrug-resistant genotypically characterized extended-spectrum beta-lactamase-producing Escherichia coli using an in vitro model.Semantic proximity Read ↗

Antimicrobial activity of DU-6681a, a parent compound of novel oral carbapenem DZ-2640.Semantic proximity Read ↗

In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa.Semantic proximity Read ↗

In vitro activity of OPC-17116 compared to other broad-spectrum fluoroquinolones.Semantic proximity Read ↗

In Vitro Activity of Doripenem against <i>Pseudomonas aeruginosa</i> and <i>Burkholderia cepacia</i> Isolates from both Cystic Fibrosis and Non-Cystic Fibrosis PatientsSemantic proximity Read ↗

In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.